会員登録
ログイン
【219A】Heartseed
重症心不全患者を対象とした iPS 細胞由来心筋球移植治療をはじめと する再生医療等製品の研究・開発
類似企業：
【業界1位】
武田薬品工業
【業界1位】
武田薬品工業
売上高
営業利益
経常利益
当期利益
{{models[key].tabname}}
| 決算期 | 日付 | 予・実 | 売上高 (百万円) |
対前回 | 修正率 | 修正率 | 営業利益 (百万円) |
対前回 | 修正率 | 修正率 | 経常利益 (百万円) |
対前回 | 修正率 | 修正率 | 当期利益 (百万円) |
対前回 | 修正率 | 修正率 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026.12 | 2026/08/14 | Q2予 | 467 | → | 0.0% | +3.5% | -2,207 | → | 0.0% | 0.0% | -2,155 | → | 0.0% | 0.0% | -2,158 | → | 0.0% | 0.0% |
| 2026.12 | 2026/05/15 | Q1予 | 467 | ↑ | +3.5% | +3.5% | -2,207 | → | 0.0% | 0.0% | -2,155 | → | 0.0% | 0.0% | -2,158 | → | 0.0% | 0.0% |
| 2026.12 | 2026/02/13 | 当初予 | 451 | - | - | - | -2,207 | - | - | - | -2,155 | - | - | - | -2,158 | - | - | - |
| 2025.12 | 2026/02/13 | 実 | 3,026 | ↓ | -0.0% | +26.4% | 272 | ↑ | +117.6% | +126.9% | 288 | ↑ | +121.5% | +130.1% | 190 | ↑ | +77.6% | +119.8% |
| 2025.12 | 2025/09/11 | Q3予 | 3,027 | → | 0.0% | +26.4% | 125 | ↑ | +112.4% | +112.4% | 130 | → | 0.0% | +113.6% | 107 | → | 0.0% | +111.2% |
| 2025.12 | 2025/08/14 | 修正予 | 3,027 | ↑ | +26.4% | +26.4% | - | - | - | - | 130 | ↑ | +113.6% | +113.6% | 107 | ↑ | +111.2% | +111.2% |
| 2025.12 | 2025/06/12 | Q2予 | 2,394 | → | 0.0% | 0.0% | -1,010 | → | 0.0% | 0.0% | -958 | → | 0.0% | 0.0% | -959 | → | 0.0% | 0.0% |
| 2025.12 | 2025/03/13 | Q1予 | 2,394 | → | 0.0% | 0.0% | -1,010 | → | 0.0% | 0.0% | -958 | → | 0.0% | 0.0% | -959 | → | 0.0% | 0.0% |
| 2025.12 | 2024/12/23 | 修正予 | 2,394 | - | - | - | -1,010 | - | - | - | -958 | - | - | - | -959 | - | - | - |
| 2025.10 | 2024/12/12 | 当初予 | 2,394 | - | - | - | -522 | - | - | - | -470 | - | - | - | -472 | - | - | - |
| 2024.10 | 2024/12/12 | 実 | 873 | ↑ | +470.6% | +470.6% | -1,038 | ↑ | +47.2% | +47.2% | -818 | ↑ | +54.5% | +54.5% | -812 | ↑ | +54.8% | +54.8% |
| 2024.10 | 2024/09/12 | 当初予 | 153 | - | - | - | -1,965 | - | - | - | -1,798 | - | - | - | -1,798 | - | - | - |
